In vitro effects of NIPRISAN (Nix-0699): A naturally occurring, potent antisickling agent

British Journal of Haematology

Volumn 118, Issue 1, 2002, Pages 337-343

  Iyamu, Efemwonkiekie W ^a   Turner, Ernest A ^b   Asakura, Toshio ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b ProHealth Medical Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antisickling agent; Hb solubility; Nix 0699; p50; Sickle cell disease

Indexed keywords

ALCOHOL; ANTISICKLING AGENT; DEOXYHEMOGLOBIN; HEMOGLOBIN; NIX 0699; UNCLASSIFIED DRUG; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEHYDRATION; DRUG EFFECT; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; OXYGEN DISSOCIATION CURVE; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN POLYMERIZATION; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ERYTHROCYTES; HEMOGLOBIN, SICKLE; HUMANS; OXYGEN; PLANT EXTRACTS; TIME FACTORS;

EID: 0036069296     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03593.x     Document Type: Article

References (24)

1. Development of therapeutic agents for sickle cell disease
2. Demonstration of delay time during aggregation of diluted solutions of deoxyhaemoglobin S and haemoglobin C Harlem in concentrated phosphate buffer
3. The solubility of sickle and non-sickle haemoglobins in concentrated phosphate buffer
4. Nucleation-controlled aggregation of deoxyhaemoglobin S: Possible difference in the size of nuclei in different phosphate concentrations
5. Kinetics of the polymerisation of haemoglobin in high and low phosphate buffers
6. Co-operative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea
7. Automated method for determination of oxygen equilibrium curves of red cell suspension under controlled buffered conditions and its clinical applications
8. Denatured haemoglobin in sickle erythrocytes
9. Neurobiology and treatment of pain
10. The effect of carbon monoxide on red cell life span in sickle cell disease
11. The effect of methaemoglobin formation in sickle cell disease
12. Hydroxyurea: Effects on Haemoglobin F production in patients with sickle cell anemia
13. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia and the investigators of the multicenter study of hydroxyurea in sickle cell anemia
14. Sickle cell haemoglobin polymerisation
15. The use of oxygen dissociation curve analyser in transfusion therapy
16. Hydroxyurea increases fetal haemoglobin in cultured erythroids cells derived from normal individuals and patients with sickle cell anemia or β-thalassemia
17. Morphological studies of sickled erythrocytes by image analysis
18. Effects of hyperbaric oxygenation on sickle syndromes
19. The pharmacology of haemoglobin switching of mice and men
20. Development of drug therapy
21. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders
22. Requirement of the therapeutic inhibition of sickle cell Hb gelation
23. Double-blind placebo, randomised cross-over clinical trial of NIPRISAN in patients with sickle cell disorders
24. Efficacy of NIPRISAN in the prophylactic management of patients with sickle cell disease